Q-omics provides the consensus-scored MT1IP profile across patient tissues and cancer cell-line models. MT1IP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MT1IP is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MT1IP RNA expression shows 7,362 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where MT1IP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1IP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1IP survival associations across molecular data types. MT1IP RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1IP RNA expression–survival associations across cancer types. High MT1IP expression shows unfavorable associations in STAD, UCS and LAML, but favorable associations in MESO, THCA and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify MESO as the clearest survival context for MT1IP RNA expression.
This table summarizes MT1IP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MT1IP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1IP shows lower tumor expression in KIRC, KIRP, THCA, KICH and COAD and higher tumor expression in UCEC. The KIRC box plot shows higher MT1IP RNA expression in normal versus tumor tissue (log2 FC = −0.395, t-test p < 0.001).
This table shows molecular features associated with MT1IP in patient tissues and cancer cell lines. In patient samples, MT1IP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
